Home-grown pharma major Lupin Ltd on Wednesday said it has entered into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets, a novel gastrointestinal drug, in the Indian market. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India, the company said in a regulatory filing.

本土制药公司major Lupin Ltd周三表示，已与武田制药有限公司签订非排他性专利许可协议，将新型胃肠道药物Vonoprazan片剂在印度市场商业化。该公司在一份监管文件中表示，根据该协议的条款，武田已授予卢平在印度商业化Vonoprazan的非排他性专利许可权。

The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths -- 10 mg and 20 mg, it added. Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders. The pact with Takeda is 'a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients,' he added.

该药物将以Lupin's Lupivon品牌销售，并将提供两种强度-10毫克和20毫克，它补充道。卢平总统印度地区配方Rajeev Sibal说，Vonoprazan是一种治疗酸性消化性疾病的新选择。他补充说，与武田达成的协议是“加强我们胃肠学组合的又一步，符合我们推出创新药物以满足患者未满足需求的承诺”。

In India, Vonoprazan is approved by the DCGI (Drugs Controller General of India) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment, Lupin said in the filing.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

卢平在文件中说，在印度，Vonoprazan被DCGI（印度药品监督管理局）批准用于治疗反流性食管炎、胃溃疡、十二指肠溃疡，并作为根除幽门螺杆菌治疗的一部分。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。